ATLANTA, Jan. 20 /CNW/ -- CeloNova BioSciences, Inc. ("CeloNova"),
leading and accelerating healthcare solutions through the provision and
development of innovative medical devices, has released data from THE SPHERE,
an 11 center, 8 country European study of uterine fibroid embolization using
the Company's Embozene(TM) Microspheres. The study results were reported at
the 20th Annual International Symposium on Endovascular Therapy.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU001 )
Patients in the study were followed for six months. According to one of
the Principal Investigators, Joachim Kettenbach, MD, Medical University of
Vienna, "Technical success was achieved in 98% of the patients. The side-
effects of fibroids such as pain and heavy menstrual bleeding were
significantly reduced while the patients' quality of life improved
Embolization is a minimally invasive procedure for uterine fibroids
during which an Interventional Radiologist injects microspheres through a tiny
catheter to the site of the fibroid. The microspheres -- each about the size
of a period at the end of this sentence -- block the blood flow to the
fibroids causing them to atrophy. The procedure is an alternative for most
women with fibroids to surgical procedures such as hysterectomy or myomectomy.
Recovery time is measured in days rather than weeks.
CeloNova's Embozene(TM) Color-Advanced Microspheres are the only
microspheres that are color-coded by size. They have a hydrogel center and an
outer layer of the Company's proprietary coating, Polyzene(R)-F which enhances
"From the beginning, CeloNova has operated on the principle that our
products would give first-rate clinical outcomes for patients and meet the
real-world needs of physicians," said Thomas A. Gordy, President and Chief
Executive Officer. Gordy continued, "This study shows that Embozene(TM)
Microspheres embody that philosophy; reducing patients' symptoms while
improving their quality of life. Color-coding improves patient safety while
simplifying the job of those performing the procedure."
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences,
Inc., is a developer of novel medical devices based on the company's patented
Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious,
anti-inflammatory, and bacterial-resistant making it an ideal surface
treatment for implanted medical devices. The company's current product
portfolio includes its Embozene(TM) Color-Advanced Microspheres and the
CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other
innovative devices are currently in the company's developmental pipeline. For
more information, please visit www.celonova.com.
Thomas A. Gordy
President and Chief Executive Officer
For further information:
For further information: Thomas A. Gordy, President and Chief Executive
Officer of CeloNova BioSciences, Inc., +1-770-502-0304 Web Site: